

Krepischi Ana Cristina Victorino (Orcid ID: 0000-0003-2931-8605)
Malaquias Alessandra (Orcid ID: 0000-0003-1514-0244)
Jorge Alexander Augusto de Lima (Orcid ID: 0000-0003-2567-7360)

High frequency of genetic/epigenetic disorders in short stature children born with very low birth weight

Running title: Genetics in VLBW children

Bruna Lucheze Freire^{1,2*}; Thais Kataoka Homma^{1,2*}; Antônio Marcondes Lerario³; Go Hun Seo⁴; Heonjong Han⁴; Mariana Ferreira de Assis Funari^{1,2}; Nathalia Lisboa Gomes⁵; Carla Rosemberg⁶; Ana Cristina Victorino Krepischi⁶; Gabriela de Andrade Vasques^{1,2}; Alessandra Christianne Malaquias^{1,7}; Alexander Augusto de Lima Jorge^{1,2}.

* - B.L.F. and T.K.H. equally contributed to the article.

1- Unidade de Endocrinologia Genética (LIM25), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (FMUSP), Brasil

2- Unidade de Endocrinologia do Desenvolvimento, Laboratório de Hormônios e Genética Molecular LIM42, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (FMUSP), Brasil

3- Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI 48109, USA

4- Division of Medical Genetics, 3billion Inc., Seoul, South Korea.

5- Unidade de Endocrinologia, Santa Casa de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil.

6- Department of Genetics & Evolutionary Biology, Biosciences Institute, University of São Paulo, São Paulo, Brazil

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/ajmg.a.62892](https://doi.org/10.1002/ajmg.a.62892)

This article is protected by copyright. All rights reserved.

7- Unidade de Endocrinologia Pediátrica, Departamento de Pediatria, Irmandade da Santa Casa de Misericórdia de São Paulo, Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, Brasil

Correspondence: Alexander Augusto de Lima Jorge, MD, PhD

Address: Avenida Dr. Arnaldo, 455, 5º andar, sala 5340, 01246-903, Sao Paulo, Brazil

Genetic Endocrinology Unit - University of Sao Paulo

Email: alexj@usp.br

Acknowledgments: This work was supported by Grants 2013/03236–5 and 2018/10893-6 from the São Paulo Research Foundation (FAPESP); Grant 303294/2020-5 from the National Council for Scientific and Technological Development (CNPq) and by Coordination of Superior Level Staff Improvement (CAPES; Finance Code 001 to N.C.B.D. and G.A.V.). Research collaboration for whole-exome sequencing with 3billion Inc., Seoul, South Korea

Conflict of interest statement: AALJ has received consulting fees from NovoNordisk and has an independent research grant from BioMarin. The other authors declare that they have no competing financial interests.

Data availability statement: The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Author Contributions: B.L.F., T.K.H. and A.A.L.J made substantial contributions to the conception and design, acquisition of data, analysis, interpretation of data, and wrote the first draft of the manuscript. All the authors made substantial contributions to data acquisition and contributed to subsequent drafts.

Ethics statement: This study was approved by the Research Ethics Committee of the Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (Approval number 37868114.3.0000.0068 in 27/01/2015), and the patients' guardians gave written informed consent.

ABSTRACT

Most infants born with very low birth weight (VLBW, birth weight < 1500g) show spontaneous catch-up growth in postnatal life. The reasons for the absence of catch-up growth are not entirely understood. We performed a comprehensive investigation of 52 children born with VLBW. Ten children had a history of an external cause that explained the VLBW, and 5 refused genetic evaluation. Twenty-three cases were initially evaluated by a candidate gene approach. Patients with a negative result in the candidate gene approach (n=14) or without clinical suspicion (n=14) were assessed by chromosome microarray analysis (CMA) and/or whole-exome sequencing (WES). A genetic condition was identified in 19 out of 37 (51.4%) of the patients without an external cause, nine by candidate gene approach and ten by a genomic approach (CMA/WES). Silver-Russell syndrome was the most frequent diagnosis (n=5), and the remaining patients were diagnosed with other rare monogenic conditions. Almost all patients with a positive genetic diagnosis exhibited syndromic features (94.4%). However, microcephaly, neurodevelopmental disorders, major malformation, or facial dysmorphism were also frequently observed in children with an external cause. In conclusion, a significant proportion of children born with VLBW with persistent short stature have a genetic/epigenetic condition.

Keywords: genetics; very low birth weight; short stature; next-generation sequencing.

INTRODUCTION

Infants born with very low birth weight (VLBW) are those with birth weight less than 1500g, and most of them are born very preterm (VP; gestational age <32 weeks) and born small for gestational age (SGA, birth weight and/or length \leq -2SDS) or both. Often, infants born with VLBW have an external factor or a uteroplacental cause that justifies prematurity and/or intrauterine growth retardation (IUGR). Additionally, extrauterine growth retardation due to feed difficulties and acute illnesses contributes to growth deficits during infancy (Wit et al 2006). Despite these adverse neonatal events, more than 80% of children born with VLBW show spontaneous catch-up growth in postnatal life (Arai et al 2019; Hollanders et al 2017). The lack of spontaneous growth recovery is frequently undetermined after usual investigation, including clinical, laboratory and radiological assessment (Boguszewski et al 2011; Collett-Solberg et al 2019a). It is expected that among children born with VLBW without catch-up growth, a genetic cause could explain the observed growth failure (Finken et al 2018).

Establishing the precise diagnosis for children born with VLBW is especially important for treatment decisions, prognosis, and genetic counseling for the affected patients and their families (Homma et al 2019; Yaghootkar and Freatly 2012). So then, in the present study, we aimed at investigating the etiology of short stature in a cohort of children born with VLBW without catch-up growth. Our results highlight the importance of clinical recognition of imprinting disorder for the correct molecular-genetic investigation and the use of chromosomal microarray analysis (CMA) and whole exome sequencing (WES) to investigate patients without an apparent external cause explain the low birth weight or the prematurity.

PATIENTS AND METHODS

This study was approved by the Research Ethics Committee of the *Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo* (Approval number 37868114.3.0000.0068 in 27/01/2015), and the patients' guardians gave written informed consent. The initial cohort consisted of 52 children born with VLBW referred for short stature investigation in our tertiary care hospital. Patients were considered VLBW with birth weight less than 1500g according to World Health Organization (WHO) classification. We reviewed the detailed gestational data and collected information regarding neonatal outcomes. Also, we collected information regarding neonatal outcomes, including gestational age, sex, birth weight, length, head circumference, early neonatal complications, drug or surgical treatments, and length of hospitalization. All children underwent a standard evaluation for children with short stature (Collett-Solberg et al 2019b). We used the Netchine-Harbison clinical scoring system (Wakeling et al 2017) to select children for Silver-Russell syndrome (SRS) investigation. Anthropometric data were converted to standard deviation score (SDS) using a gender-specific norm (Kuczmarski et al 2000). The target height was calculated $[(\text{father's height} + \text{mother's height} \pm 13 \text{ cm})/2]$ and expressed as SDS.

Genomic DNA was extracted from peripheral blood leukocytes using standard procedures. Fifteen children were clinically diagnosed and submitted to targeted genetic analysis. Patients with clinical diagnosis (score ≥ 4 , n = 6) or clinical suspicion (score = 3, n = 8) of SRS (Wakeling et al 2017) were evaluated by Methylation-Specific Multiplex ligation-dependent Probe Amplification (MS-MLPA ME030 BWS/RSS; MRC-Holland). The other nine cases were clinically diagnosed as having monogenic conditions and were evaluated by a targeted panel (Freire et al 2019). Negative results and patients without clinical suspicion were submitted to CMA and/or WES (Figure 1). Microarray comparative genomic hybridization (aCGH) was performed in a whole-genome 180 K platform (Agilent Technologies, Inc., Santa Clara, CA, USA). Microarray-scanned images were processed using the

software Genomic Workbench (Agilent Technologies, Inc.). The parameters used to call a duplication, or a deletion and pathogenicity analysis followed previous studies (Homma et al 2018). WES was performed with genomic libraries constructed using SureSelect Target Enrichment System (Agilent Technologies, Santa Clara, USA) or xGen Exome Research Panel v2 (Integrated DNA Technologies, Coralville, Iowa, USA). Sequences were generated in the Illumina HiSEQ 2500 or Novaseq 6000 (Illumina, Inc, San Diego, CA, USA) platform running on paired-end mode. Alignment, variant call, and data screening for deleterious single nucleotide variants (SNVs) and small in/dels were performed according to previously published protocols (Freire et al 2019; Homma et al 2019; Seo et al 2020). Copy number variants (CNVs) analysis based on WES data was performed by clinCNV and Delly (Demidov and Ossowski 2019; Rausch et al 2012). Variant interpretation followed the ACMG/AMP variant pathogenicity guideline (Richards et al 2015).

Patients were separated into three groups: 1) External cause factor for IUGR/prematurity (maternal or fetoplacental factors); 2) positive genetic cause; and 3) undiagnosed patients. Comparisons were made by ANOVA or ANOVA on Ranks, as appropriate. Nominal variables were compared by Chi-square. Data were analyzed by SigmaStat version 4.0 (Systat Software Inc. Chicago, IL). A p-value <.05 was considered statistically significant.

RESULTS

We analyzed data from 52 patients born with VLBW referred due to growth disorder. The clinical characteristics of the studied group are presented in Table 1. The median gestational age was 30.5 weeks, ranging from 26 to 39.2 weeks; most were VP (65.4%). The mean birth weight was 1,067 grams (500 to 1,490), and 44.2% were born small for gestational age. No chronic systemic diseases or endocrine disorders were identified in our whole cohort following the standard assessment for short stature. Five patients refused genetic investigation (Figure 1). Ten patient had an evident history of external cause, as

eclampsia (n=4); multiple gestation (n=2); history of maternal substance abuse (n=2); placenta abruption (n=1); or fetal distress (n=1). Among these patients, eight were analyzed by targeted panel sequencing (Freire et al 2019) and two underwent WES. None pathogenic or likely pathogenic variants were identified in these patients with a clear external cause explaining the prematurity or IUGR.

Among the 37 patients without an evident history of external cause, we detected an underlying genetic condition in 51.4% (19/37) (Figure 1 and Table 2). There were no statistical differences among groups (Table 1), except for birth length (patients with a genetic diagnosis had more preserved birth length) and syndromic features, which were more frequently observed in patients with positive genetic findings.

Twenty-three patients had a clinical suspicion of a specific genetic syndrome and were submitted to targeted genetic analysis. SRS was the most suspected condition (OMIM#180860; n=14); the others were clinically diagnosed as Noonan syndrome (OMIM#610733; n=3), Bloom syndrome (OMIM#210900), Resistance to IGF-1 (OMIM#270450), Aarskog-Scott syndrome (OMIM#305400), Coffin-siris syndrome (OMIM#135900), IMAGE syndrome (OMIM#614732), and pseudohypoparathyroidism (OMIM#612463) (one each). The clinical diagnosis was confirmed by genetic results in 5 of 9 patients suspected of a monogenic syndromic condition. Among patients evaluated for molecular abnormalities of chromosome 11p15.5; four of 6 patients with clinical diagnosis (score ≥ 4 , n = 6) and none of the patients with clinical suspicion of SRS (score = 3) had a molecular confirmation (Figure 1). Fourteen patients with negative targeted analysis and fourteen patients without initial clinical suspicion were selected for genomic approaches. Among these 28 patients, the molecular diagnosis was achieved in 10 cases (36%). Three patients had a pathogenic CNV detected by CMA (a deletion; a duplication and one case with deletion and duplication), and seven had a rare monogenic condition (Table 2): resistance to IGF1 (OMIM#270450), Microcephalic Osteodysplastic Primordial Dwarfism type II (MOPD2) (OMIM#210720), Baraitser-Winter syndrome 1 (OMIM#243310),

Centronuclear myopathy (OMIM#160150), Autosomal Recessive Dyskeratosis Congenita 4 (OMIM#613989), Silver-Russell Syndrome 5 (OMIM# 618908); and Neurodevelopmental-craniofacial syndrome with variable renal and cardiac abnormalities (OMIM#619522). All patients had a phenotype compatible with the molecular diagnosis.

DISCUSSION

Nowadays, the leading cause of infant mortality worldwide remains perinatal causes; however, the advances in the management of pregnancy complications and neonatal intensive care have improved survival rates (Crump 2020). Therefore, the number of infants born with VLBW has steadily increased over the years, and a significant adverse outcome is postnatal short stature (Arai et al 2019; Van de Pol and Allegaert 2020). Although the absence of catch-up growth and consequent postnatal short stature may be related to the extrauterine growth retardation, a genetic cause can also be related to postnatal growth disorder (Finken et al 2018).

We analyzed a group of short-stature children born with VLBW. The etiology of short stature was established in 55.7% of these patients; among them, 35.7% (n=10) had an external evident cause associated with low birth weight/prematurity, and 65.5% (n = 19) had a genetic/epigenetic disease (Figure 1). Our findings showed the importance of a complete prenatal and detailed gestational anamnesis; in the absence of a recognized external cause for this condition, the genetic/epigenetic causes represent a major factor associated with VLBW.

Among children with clinical diagnosis or suspicion of a specific condition, the targeted genetic analyses confirmed the initial hypothesis in 39% of the cases. If we excluded the patients selected for chromosome 11p15.5 analyses due to a score of 3 in Netchine-Harbison clinical scoring system for SRS; the confirmation rate rises to 60% of cases selected for candidate gene approach, reassuring the relevance of specialized genetic evaluation before indicating the molecular exam (Mintz et al 2021). This is

Author Manuscript

particularly important in the recognition of cases of imprinting disorders. Conditions such as SRS and Temple syndrome are associated with intrauterine growth retardation and demand specific molecular-genetic investigation (Wakeling et al 2017). Indeed, SRS was one of the most frequently established molecular diagnoses in our cohort (n=5, Table 2), with four patients diagnosed during a specific diagnostic test for SRS. Regarding children without a clinical suspicion, the diagnostic rate was 36%, involving chromosomal alteration and a variety of rare monogenic diseases associated with a growth disorder. The diagnostic yield was similar to other studies that evaluated children with growth disorders supporting the use of CMA and WES in clinical practice when evaluating short-stature children born with VLBW (Mintz et al 2021).

The strengths of this analysis include the evaluation of a relatively large cohort of children born at VLBW with a persistent growth disorder. We applied the current guidelines for clinical and genetic investigation of growth disorders (Collett-Solberg et al 2019a; Dauber 2019; Finken et al 2018; Mintz et al 2021). However, our study had some limitations that should be mentioned. First, patients referred to our tertiary center can represent the most severe cases with a high frequency of genetic/epigenetic disorders. Another potential limiting factor is that not all patients were molecularly evaluated for SRS or had WES/CMA analysis. However, despite these limitations, the present study highlights the importance of clinical investigation linked to genetic tests to establish the diagnosis in this growing group of children with growth disorders.

In conclusion, children born VLBW who do not have catch-up growth have a high frequency of genetic/epigenetic causes, particularly SRS. In the absence of criteria for investigation of SRS or a clear external cause, genetic evaluation using a multigene approach, preferably WES with SNVs and CNVs analysis, allows obtaining the etiological diagnosis in a significant portion of the cases.

REFERENCES

- Arai S, Sato Y, Muramatsu H, Yamamoto H, Aoki F, Okai Y, Kataoka S, Hanada Y, Hamada M, Morimoto Y, Kojima S, Natsume J, Takahashi Y, Nagoya Collaborative Clinical Research T. (2019). Risk factors for absence of catch-up growth in small for gestational age very low-birthweight infants. *Pediatr Int* 61, 889-894. <https://doi.org/10.1111/ped.13939>
- Boguszewski MC, Mericq V, Bergada I, Damiani D, Belgorosky A, Gunczler P, Ortiz T, Llano M, Domene HM, Calzada-Leon R, Blanco A, Barrientos M, Procel P, Lanes R, Jaramillo O. (2011). Latin American consensus: children born small for gestational age. *BMC Pediatr* 11, 66. <https://doi.org/10.1186/1471-2431-11-66>
- Collett-Solberg PF, Ambler G, Backeljauw PF, Bidlingmaier M, Biller BMK, Boguszewski MCS, Cheung PT, Choong CSY, Cohen LE, Cohen P, Dauber A, Deal CL, Gong C, Hasegawa Y, Hoffman AR, Hofman PL, Horikawa R, Jorge AAL, Juul A, Kamenicky P, Khadilkar V, Kopchick JJ, Kristrom B, Lopes MLA, Luo X, Miller BS, Misra M, Netchine I, Radovick S, Ranke MB, Rogol AD, Rosenfeld RG, Saenger P, Wit JM, Woelfle J. (2019a). Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective. *Horm Res Paediatr* 92, 1-14. <https://doi.org/10.1159/000502231>
- Collett-Solberg PF, Jorge AAL, Boguszewski MCS, Miller BS, Choong CSY, Cohen P, Hoffman AR, Luo X, Radovick S, Saenger P. (2019b). Growth hormone therapy in children; research and practice - A review. *Growth Horm IGF Res* 44, 20-32. <https://doi.org/10.1016/j.ghir.2018.12.004>
- Crump C. (2020). An overview of adult health outcomes after preterm birth. *Early Hum Dev* 150, 105187. <https://doi.org/10.1016/j.earlhumdev.2020.105187>
- Dauber A. (2019). Genetic Testing for the Child With Short Stature-Has the Time Come To Change Our Diagnostic Paradigm? *J Clin Endocrinol Metab* 104, 2766-2769. <https://doi.org/10.1210/jc.2019-00019>
- Demidov G, Ossowski S. (2019). ClinCNV: novel method for allele-specific somatic copy-number alterations detection. *bioRxiv*, 837971. <https://doi.org/10.1101/837971>
- Finken MJJ, van der Steen M, Smeets CCJ, Walenkamp MJE, de Bruin C, Hokken-Koelega ACS, Wit JM. (2018). Children Born Small for Gestational Age: Differential Diagnosis, Molecular Genetic Evaluation, and Implications. *Endocr Rev* 39, 851-894. <https://doi.org/10.1210/er.2018-00083>
- Freire BL, Homma TK, Funari MFA, Lerario AM, Vasques GA, Malaquias AC, Arnhold IJP, Jorge AAL. (2019). Multigene Sequencing Analysis of Children Born Small for Gestational Age With Isolated Short Stature. *J Clin Endocrinol Metab* 104, 2023-2030. <https://doi.org/10.1210/jc.2018-01971>
- Hollanders JJ, van der Pal SM, van Dommelen P, Rotteveel J, Finken MJJ. (2017). Growth pattern and final height of very preterm vs. very low birth weight infants. *Pediatr Res* 82, 317-323. <https://doi.org/10.1038/pr.2017.63>

- Homma TK, Freire BL, Honjo Kawahira RS, Dauber A, Funari MFA, Lerario AM, Nishi MY, Albuquerque EV, Vasques GA, Collett-Solberg PF, Miura Sugayama SM, Bertola DR, Kim CA, Arnhold IJP, Malaquias AC, Jorge AAL. (2019). Genetic Disorders in Prenatal Onset Syndromic Short Stature Identified by Exome Sequencing. *J Pediatr* 215, 192-198. <https://doi.org/10.1016/j.jpeds.2019.08.024>
- Homma TK, Krepischi ACV, Furuya TK, Honjo RS, Malaquias AC, Bertola DR, Costa SS, Canton AP, Roela RA, Freire BL, Kim CA, Rosenberg C, Jorge AAL. (2018). Recurrent Copy Number Variants Associated with Syndromic Short Stature of Unknown Cause. *Horm Res Paediatr* 89, 13-21. <https://doi.org/10.1159/000481777>
- Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, Mei Z, Curtin LR, Roche AF, Johnson CL. (2000). CDC growth charts: United States. *Adv Data*, 1-27.
- Mintz CS, Seaver LH, Irons M, Grimberg A, Lozano R, Practice AP, Guidelines C. (2021). Focused Revision: ACMG practice resource: Genetic evaluation of short stature. *Genet Med* 23, 813-815. <https://doi.org/10.1038/s41436-020-01046-0>
- Rausch T, Zichner T, Schlattl A, Stütz AM, Benes V, Korbel JO. (2012). DELLY: structural variant discovery by integrated paired-end and split-read analysis. *Bioinformatics* 28, i333-i339. <https://doi.org/10.1093/bioinformatics/bts378>
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, Committee ALQA. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 17, 405-424. <https://doi.org/10.1038/gim.2015.30>
- Seo GH, Kim T, Choi IH, Park JY, Lee J, Kim S, Won DG, Oh A, Lee Y, Choi J, Lee H, Kang HG, Cho HY, Cho MH, Kim YJ, Yoon YH, Eun BL, Desnick RJ, Keum C, Lee BH. (2020). Diagnostic yield and clinical utility of whole exome sequencing using an automated variant prioritization system, EVIDENCE. *Clin Genet* 98, 562-570. <https://doi.org/10.1111/cge.13848>
- Van de Pol C, Allegaert K. (2020). Growth patterns and body composition in former extremely low birth weight (ELBW) neonates until adulthood: a systematic review. *Eur J Pediatr* 179, 757-771. <https://doi.org/10.1007/s00431-019-03552-z>
- Wakeling EL, Brioude F, Lokulo-Sodipe O, O'Connell SM, Salem J, Bliet J, Canton AP, Chrzanowska KH, Davies JH, Dias RP, Dubern B, Elbracht M, Giabicani E, Grimberg A, Grønskov K, Hokken-Koelega AC, Jorge AA, Kagami M, Linglart A, Maghnie M, Mohnike K, Monk D, Moore GE, Murray PG, Ogata T, Petit IO, Russo S, Said E, Toumba M, Tümer Z, Binder G, Eggermann T, Harbison MD, Temple IK, Mackay DJ, Netchine I. (2017). Diagnosis and management of Silver-Russell syndrome: first international consensus statement. *Nat Rev Endocrinol* 13, 105-124. <https://doi.org/10.1038/nrendo.2016.138>

Wit JM, Finken MJ, Rijken M, de Zegher F. (2006). Preterm growth restraint: a paradigm that unifies intrauterine growth retardation and preterm extrauterine growth retardation and has implications for the small-for-gestational-age indication in growth hormone therapy. *Pediatrics* 117, e793-795.

<https://doi.org/10.1542/peds.2005-1705>

Yaghootkar H, Freathy RM. (2012). Genetic origins of low birth weight. *Curr Opin Clin Nutr Metab Care* 15, 258-264. <https://doi.org/10.1097/MCO.0b013e328351f543>




Figure 1: Flowchart of the approach used in this study to investigate children with short stature and born with VLBW. * - Netchine-Harbison clinical scoring system for Silver-Russell (SRS) evaluation (Wakeling et al 2017)

Table 1: Clinical characteristics of a cohort of children born at very low birth weight.

	Total patients N=52	External cause N=10	Genetic cause N=19	Undiagnosed patients N=23	P
Sex (m/f)	34/18	7/3	10/9	17/6	0.333
Gestational age (weeks)	30.9 ±3.6	30.7 ±3.3	32.1 ±4.2	30.0 ±2.9	0.189
Birth weight SDS	-2.1 ±1.9	-2.6 ±1.9	-2.0 ±1.8	-1.9 ±2.0	0.645
Birth length SDS	-3.3 ±2.7	-4.6 ±3.8	-1.9 ±2.5	-3.9 ±1.8	0.027^a
Very premature (%)	34 (65.4)	6 (60.0)	10 (52.6)	18 (78.3)	0.204
Small for gestational age (%)	23 (44.2)	3 (30.0)	9 (47.4)	11 (47.8)	0.601
Age at the 1 st evaluation (years)	6.8 ± 5.4	6.5 ±3.0	7.6 ±7.0	6.2 ±4.7	0.707
Height SDS	-3.3 ±1.5	-3.1 ±0.9	-3.3 ±1.3	-3.5 ±1.8	0.806
Height SDS - target height	-2.2 ±1.4	-2.0 ±0.6	-2.3 ±1.8	-2.1 ±1.3	0.838
BMI SDS	-1.7 ±2.0	-1.4 ±1.8	-2.3 ±2.1	-1.3 ±1.9	0.248
Syndromic features (%)	38 (73.1)	5 (50.0)	18 (94.7)	15 (65.2)	0.019
Facial dysmorphism (%)	30 (57.7)	3 (30.0)	12 (63.2)	15 (65.2)	0.142
Neurodevelopmental disorders (%)	22 (42.3)	4 (40.0)	9 (47.4)	9 (39.1)	0.854
Microcephaly (%)	23 (44.2)	3 (30.0)	8 (42.1)	12 (52.2)	0.486
Major malformation (%)	16 (30.8)	1 (10.0)	6 (31.6)	9 (39.1)	0.248
Skeletal dysplasia (%)	2 (3.8)	0	1 (5.3)	1 (4.3)	0.761
Short-stature parent (%)	9/49 (18.3)	2/9 (22.2)	2/18 (11.1)	5/23 (21.7)	0.329
Consanguinity (%)	2/50 (4.0)	0	1 (5.3%)	1 (4.3)	0.772


a. Student-Newman-Keuls post hoc test: p = 0.022 Genetic cause vs. Undiagnosed and p = 0.059 Genetic cause vs. External cause

Table 2: Pathogenic variants detected in 19 children born at very low birth weight.


ID	Gene/Locus	Variant	Zygosity (Inheritance)	Final diagnoses (OMIM)
Positive results in candidate gene approach				
1-3	11p15.5	Hypomethylation of <i>H19/IGF2</i> IG-HMR	NA	Silver-Russell syndrome (180860)
4	11.p15.5	arr[GRCh37] Arr 11p15.5p15.4(2029155-2916802)x3	Heterozygous (Inherited from unaffected mother)	Silver-Russell syndrome (180860)
5	<i>BLM</i>	exons 20-22 deletion	Homozygous (Autosomal recessive)	Bloom syndrome (210900)
6	<i>PTPN11</i>	NM_002834.5:c.218C>T.p.Thr73Ile	Heterozygous (NA)	Noonan syndrome 1 (163950)
7	<i>GNAS</i>	NM_080425.3:c.2682C>G.p.Ser894Arg	Heterozygous (<i>de novo</i>)	Pseudopseudohypoparathyroidism (612463)
8	<i>IGF1R</i>	NM_000875.5:c.202G>T.p.Glu68*	Heterozygous (Inherited from affected mother)	Resistance to Insulin-like growth factor I (270450)
9	<i>SOS1</i>	NM_005633.4:c.1297G>A.p.Glu433Lys	Heterozygous (NA)	Noonan syndrome 4 (610733)
Positive results in CMA^a				
10	4p16.3	arr[GRCh37]4p16.3(49450-2559990)x1	Heterozygous (<i>de novo</i>)	Wolf-Hirschhorn syndrome (194190)
11	13q21.33q34	arr[GRCh37]13q21.33q34 (70141036-113656958)x3 arr[GRCh37]13q34(113759040-114123122)x1	Heterozygous (NA)	
12	Xq13.1-q13.2	arr[GRCh37]Xq13.1-q13.2 (71470619-73377808)x2	Hemizygous (<i>de novo</i>)	
Positive results in WES				
13	<i>ACTB</i>	NM_001101.5:c.616C>T.p.Arg206Trp	Heterozygous (NA)	Baraitser-Winter syndrome 1 (243310)
14	<i>IGF1R</i>	NM_000875.5:c.2629C>T.p.Arg877*	Heterozygous (Inherited from affected father)	Resistance to Insulin-like growth factor I (270450)

15	<i>PCNT</i>	NM_006031.6:c.8413C>T;p.Gln2805* NM_006031.6:c.9099G>C;p.Gln3033His	Compound heterozygous	Microcephalic osteodysplastic primordial dwarfism, type II (210720)
16	<i>DNM2</i>	NM_001005361.3:c.1102G>A;p.Glu368Lys	Heterozygous (NA)	Centronuclear myopathy 1 (160150)
17	<i>HMGA2</i>	NM_003483.6:c.198+1G>C	Heterozygous (Inherited from affected mother)	Silver-Russell syndrome 5 (618908)
18	<i>TERT</i>	NM_198253.3:c.2911C>T;p.Arg971Cys NM_198253.3:c.2780T>G;p.Leu927Arg	Compound heterozygous	Autosomal Recessive Dyskeratosis congenita (613989)
19	<i>ZMYM2</i>	NM_197968.4:c.2459-1G>T	Heterozygous (Inherited from her mother)	Neurodevelopmental-craniofacial syndrome with variable renal and cardiac abnormalities (619522)

NA – not available



AJMGA_62892_Figure 1 (18-01-2022).tif



AJMGA_62892_Figure 1 (25-04-2022).tif

Table 1: Clinical characteristics of a cohort of children born at very low birth weight.

	Total patients N=52	External cause N=10	Genetic cause N=19	Undiagnosed patients N=23	P
Sex (m/f)	34/18	7/3	10/9	17/6	0.333
Gestational age (weeks)	30.9 ±3.6	30.7 ±3.3	32.1 ±4.2	30.0 ±2.9	0.189
Birth weight SDS	-2.1 ±1.9	-2.6 ±1.9	-2.0 ±1.8	-1.9 ±2.0	0.645
Birth length SDS	-3.3 ±2.7	-4.6 ±3.8	-1.9 ±2.5	-3.9 ±1.8	0.027^a
Very premature (%)	34 (65.4)	6 (60.0)	10 (52.6)	18 (78.3)	0.204
Small for gestational age (%)	23 (44.2)	3 (30.0)	9 (47.4)	11 (47.8)	0.601
Age at the 1 st evaluation (years)	6.8 ± 5.4	6.5 ±3.0	7.6 ±7.0	6.2 ±4.7	0.707
Height SDS	-3.3 ±1.5	-3.1 ±0.9	-3.3 ±1.3	-3.5 ±1.8	0.806
Height SDS - target height	-2.2 ±1.4	-2.0 ±0.6	-2.3 ±1.8	-2.1 ±1.3	0.838
BMI SDS	-1.7 ±2.0	-1.4 ±1.8	-2.3 ±2.1	-1.3 ±1.9	0.248
Syndromic features (%)	38 (73.1)	5 (50.0)	18 (94.7)	15 (65.2)	0.019
Facial dysmorphism (%)	30 (57.7)	3 (30.0)	12 (63.2)	15 (65.2)	0.142
Neurodevelopmental disorders (%)	22 (42.3)	4 (40.0)	9 (47.4)	9 (39.1)	0.854
Microcephaly (%)	23 (44.2)	3 (30.0)	8 (42.1)	12 (52.2)	0.486
Major malformation (%)	16 (30.8)	1 (10.0)	6 (31.6)	9 (39.1)	0.248
Skeletal dysplasia (%)	2 (3.8)	0	1 (5.3)	1 (4.3)	0.761
Short stature parent (%)	9/49 (18.3)	2/9 (22.2)	2/18 (11.1)	5/23 (21.7)	0.329
Consanguinity (%)	2/50 (4.0)	0	1 (5.3%)	1 (4.3)	0.772

a. Student-Newman-Keuls post hoc test: p = 0.022 Genetic cause vs. Undiagnosed and p = 0.059 Genetic cause vs. External cause

Table 2: Pathogenic variants detected in 19 children born at very low birth weight.

ID	Gene/Locus	Variant	Zygoty (Inheritance)	Final diagnoses (OMIM)
Positive results in candidate gene approach				
1-3	11p15.5	Hypomethylation of <i>H19/IGF2</i> IG-HMR	NA	Silver-Russell syndrome (180860)
4	11.p15.5	arr[GRCh37] Arr 11p15.5p15.4(2029155-2916802)x3	Heterozygous (Inherited from unaffected mother)	Silver-Russell syndrome (180860)
5	<i>BLM</i>	exons 20-22 deletion	Homozygous (Autosomal recessive)	Bloom syndrome (210900)
6	<i>PTPN11</i>	NM_002834.5:c.218C>T;p.Thr73Ile	Heterozygous (NA)	Noonan syndrome 1 (163950)
7	<i>GNAS</i>	NM_080425.3:c.2682C>G;p.Ser894Arg	Heterozygous (<i>de novo</i>)	Pseudopseudohypoparathyroidism (612463)
8	<i>IGF1R</i>	NM_000875.5:c.202G>T;p.Glu68*	Heterozygous (Inherited from affected mother)	Resistance to Insulin-like growth factor I (270450)
9	<i>SOS1</i>	NM_005633.4:c.1297G>A;p.Glu433Lys	Heterozygous (NA)	Noonan syndrome 4 (610733)
Positive results in CMA^a				
10	4p16.3	arr[GRCh37]4p16.3(49450-2559990)x1	Heterozygous (<i>de novo</i>)	Wolf-Hirschhorn syndrome (194190)
11	13q21.33q34	arr[GRCh37]13q21.33q34 (70141036-113656958)x3 arr[GRCh37]13q34(113759040-114123122)x1	Heterozygous (NA)	
12	Xq13.1-q13.2	arr[GRCh37]Xq13.1-q13.2 (71470619-73377808)x2	Hemizygous (<i>de novo</i>)	
Positive results in WES				
13	<i>ACTB</i>	NM_001101.5:c.616C>T;p.Arg206Trp	Heterozygous (NA)	Baraitser-Winter syndrome 1 (243310)
14	<i>IGF1R</i>	NM_000875.5:c.2629C>T;p.Arg877*	Heterozygous (Inherited from affected father)	Resistance to Insulin-like growth factor I (270450)
15	<i>PCNT</i>	NM_006031.6:c.8413C>T;p.Gln2805* NM_006031.6:c.9099G>C;p.Gln3033His	Compound heterozygous	Microcephalic osteodysplastic primordial dwarfism, type II (210720)
16	<i>DNM2</i>	NM_001005361.3:c.1102G>A;p.Glu368Lys	Heterozygous (NA)	Centronuclear myopathy 1 (160150)
17	<i>HMGA2</i>	NM_003483.6:c.198+1G>C	Heterozygous (Inherited from affected mother)	Silver-Russell syndrome 5 (618908)
18	<i>TERT</i>	NM_198253.3:c.2911C>T;p.Arg971Cys NM_198253.3:c.2780T>G;p.Leu927Arg	Compound heterozygous	Autosomal Recessive Dyskeratosis congenita (613989)

NA – not available